Back |
home / stock / eyeg / eyeg message board
Subject | By | Source | When |
---|---|---|---|
Ever since$ EYEG announced they will consider strategic alternatives | couldbebetter | investorshub | 12/30/2019 10:30:57 PM |
* * $EYEG Video Chart 11-22-2019 * * | ClayTrader | investorshub | 11/22/2019 9:39:18 PM |
8 bitches lets go | akamaii | investorshub | 11/22/2019 6:57:57 PM |
Bought 690 lets go | akamaii | investorshub | 11/22/2019 6:32:21 PM |
TOLDDDDDDDDDD YOU SO | ADVFN_bioking | investorshub | 11/22/2019 2:25:20 PM |
then to 8.75 some stocks take days to | TheFinalCD | investorshub | 11/22/2019 2:15:51 PM |
I am watching! $EYEG... | crudeoil24 | investorshub | 11/22/2019 2:12:45 PM |
9.15 again | TheFinalCD | investorshub | 11/22/2019 2:10:55 PM |
Could see huge 11.00+ pop & drop @ | crudeoil24 | investorshub | 11/22/2019 1:52:20 PM |
swings hard just went from 8.80 to 9.75 | TheFinalCD | investorshub | 11/22/2019 1:50:21 PM |
More topline data coming in 2K20. | crudeoil24 | investorshub | 11/22/2019 1:40:36 PM |
9.01 after hitting 11 | TheFinalCD | investorshub | 11/22/2019 1:37:03 PM |
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...